Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03132259 : Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach
PhasePhase 4
AgesMin: 18 Years Max: 65 Years
Eligibility
Inclusion Criteria:

1. Age18-65

2. ASA 1-2

3. Elective TNTS resection of Pituitary Tumor

4. No narcotic before surgery as premedication

5. Able to Extubate

Exclusion Criteria:

1. GCS less than 15

2. Preoperative Heart Rate less than 50 beat/min

3. No Beta-Blockers

4. Pregnant patients

5. Take any Alpha-Methyldopa, Clonodine, Other Alpha-2 Adrenergic Agonist

6. Hemodynamic unstable

7. Systolic BP more than 160mmHg

8. CAD

9. Renal insuffuciency

10. Allergy in dexmedethomidine and opioid

11. BMI more than 30

12. Denied consent
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03132259      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740